CCM
SMMT icon

Coldstream Capital Management’s Summit Therapeutics SMMT Stock Holding History

Coldstream Capital Management’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-128
Closed -$2.47K – 3014
2025
Q1 		$2.47K Buy
+128
New +$2.57K ﹤0.01% 2940

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Coldstream Capital Management's SMMT Position: Q2 2025 in Review

Coldstream Capital Management sold out of Summit Therapeutics (SMMT) in Q2 2025, closing a stake of 128 shares — an estimated $2.47K sold.

Coldstream Capital Management first reported a position in SMMT in Q1 2025 and held it in 1 quarter. The position peaked at $2.47K in Q1 2025. 238 funds tracked by Wall St. Rank hold SMMT as of Q2 2025.

  • Coldstream Capital Management reported no remaining Summit Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Coldstream Capital Management sold 128 Summit Therapeutics shares in Q2 2025, an estimated $2.47K.
  • Coldstream Capital Management first reported a position in Summit Therapeutics in Q1 2025 and held it in 1 quarter.
  • Coldstream Capital Management's Summit Therapeutics position peaked at $2.47K in Q1 2025.
  • 238 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2025.

Based on Coldstream Capital Management's 13F filing for Q2 2025, filed 12 Aug 2025.